The short answer is yes, particularly during menopause. In fact, we can blame a lot on hormonal changes, from unexpected ...

The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

Prescriptions for hormone therapy dropped after a study suggested it could increase health risks like cancer. But experts say ...

Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

A three-drug combination targeting aggressive advanced breast cancer could potentially double the amount of time patients ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

The drug has a half-life of approximately 28 h. Raloxifene is an estrogen agonist in bone, where it exerts an antiresorption effect. The drug does not cause endometrial stimulation and ...

Alternatively, ovarian function can be suppressed temporarily by treating patients with drugs called gonadotropin-releasing hormone (GnRH) agonists, which are also known as luteinizing hormone ...

Or sign-in if you have an account. OTTAWA — Just over 100 new prescriptions for hormone-related drugs were filled last year for Albertans between the ages of 11 and 15, according to data from ...

These actions can also be observed in patients taking other currently used cholesterol-lowering drugs, such as statins. Selective thyroid hormone receptor modulation is a promising new strategy ...